Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- MHLW Partially Agrees with Gov’t Panel’s Reason for Creation of New Mixed Care Rule
June 2, 2014
- Fiscal System Council Renews Call for Annual NHI Price Revision, MHLW Still Guarded
June 2, 2014
- PAFSC’s First Committee Backs Approval of LEO Pharma’s Ointment for Psoriasis Vulgaris, Shire Japan’s Gaucher’s Disease Drug
June 2, 2014
- MHLW Announces Addition of 9 APIs/11 Products to NHI Price List Including Takeda’s Takelda
June 2, 2014
- Government Panel Officially Proposes to Relax Current Mixed Care Rule
May 30, 2014
- Chuikyo to Assess Cost-Effectiveness of 5 Listed Drugs, Industry Leery of Price Cuts
May 29, 2014
- Pharmaceuticals and Medical Devices Safety Information Calls for Proper Use of Schizophrenia Treatment Xeplion
May 29, 2014
- Integrated Guidelines Will Apply to “Research” Conducted by the Media as Well: MHLW
May 29, 2014
- J-ADNI Data Falsification “Unacceptable” If True: MHLW
May 28, 2014
- Approval for Remicade Biosimilar Products Reported to PAFSC’s Second Committee
May 28, 2014
- CRC Training Program Presented to Panel on Clinical Research Promotion
May 27, 2014
- Diet Enacts Japanese NIH-Related Bills
May 26, 2014
- MHLW to Discuss Setting Rules on OTC Switching of Diagnostics at Panel on In Vitro Diagnostics
May 23, 2014
- PAFSC’s First Committee to Review LEO Pharma’s Psoriasis Drug on May 30
May 22, 2014
- Collaborations with PMDA, Prefectures Crucial in PIC/S: MHLW
May 22, 2014
- Risk Management Plans for 8 APIs Published Since April 2013; Will Be Required for Approval of New Drugs and Biosimilars Starting October 1, 2014
May 22, 2014
- Kyowa Kirin Workers’ Clinical Study Misconduct “Utterly Unacceptable”: Minister
May 21, 2014
- MHLW, MOF, Cabinet Office to Come to Agreement on Once-yearly NHI Price Revision by End May
May 21, 2014
- Clinical Research Grants Might Fall Due to New JPMA Rule
May 20, 2014
- PIC/S Committee OKs Japan’s Accession from July 2014
May 20, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…